SCOLR Pharma To Co-Develop Flu Application

SCOLR Pharma has entered into a research collaboration with a U.S.-based biopharma company to develop an oral formulation of a promising antiviral compound using its proprietary CDT® drug delivery platform. The compound under development has the potential to be used as a treatment against influenza. The goal of the program is to enhance the bioavailability of the compound to facilitate oral administration. If successful, the parties expect to enter a license agreement, which would provide for the potential commercialization of the product.

Alan M. Mitchel, SCOLR Pharma’s senior vice president, said, “We believe this collaborative agreement is another important affirmation of the breadth of our proprietary CDT drug delivery technology. We look forward to working closely with our partner on this potentially important new pharmaceutical application. This is our fourth partnering relationship announced over the last several quarters.”